MedDataX Logo

Safety and Tolerability Study of Multiple Doses of PF-06305591

NCT ID: NCT01776619

Last Updated: 2013-12-03

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

43 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-04-30

Study Completion Date

2013-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Safety, tolerability and PK of repeated doses of PF-06305591 will be evaluated in young healthy volunteers toghether with food effect on relative bioavailability of solid formulation after single dose.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study to Investigate the Safety, Tolerability, Pharmacokinetics of PF-06305591 in Healthy Male and Female Subjects

NCT01747941

Healthy
COMPLETED PHASE1

Evaluation Of Safety, Tolerability And Pharmacokinetics Of Single And Multiple Doses Of PF-06730512

NCT03146065

Healthy
COMPLETED PHASE1

A Study In Healthy People To Evaluate Safety, Toleration, Pharmacokinetics And Pharmacodynamics Of Multiple Oral Doses Of PF-06743649

NCT02151617

Healthy
COMPLETED PHASE1

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Repeat Doses of PF-06372865 in Healthy Subjects

NCT03351751

Healthy Volunteers
COMPLETED PHASE1

A Study To Evaluate the Safety, Tolerability, And Pharmacokinetics Of PF-06266047 In Healthy Adult Subjects

NCT02539550

Healthy Volunteers
COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Multiple Dose: Cohort 1

Group Type EXPERIMENTAL

PF-06305591

Intervention Type DRUG

14 day repeated 20mg BID doses

Placebo

Intervention Type DRUG

14 day repeated BID doses

Multiple Dose: Cohort 2

Group Type EXPERIMENTAL

PF-06305591

Intervention Type DRUG

14 day repeated 80mg BID doses

Placebo

Intervention Type DRUG

14 day repeated BID doses

Multiple Dose: Cohort 3

Group Type EXPERIMENTAL

PF-06305591

Intervention Type DRUG

14 day repeated 40mg BID doses

Placebo

Intervention Type DRUG

14 day repeated BID doses

Multiple Dose: Cohort 4

Group Type EXPERIMENTAL

PF-06305591

Intervention Type DRUG

14 day repeated BID doses

Relative Bioavilability: Cohort 1

Group Type EXPERIMENTAL

PF-06305591

Intervention Type DRUG

relative bioavailability tablet vs. solution and food effect at 50mg dose

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

PF-06305591

14 day repeated 20mg BID doses

Intervention Type DRUG

Placebo

14 day repeated BID doses

Intervention Type DRUG

PF-06305591

14 day repeated 80mg BID doses

Intervention Type DRUG

Placebo

14 day repeated BID doses

Intervention Type DRUG

PF-06305591

14 day repeated 40mg BID doses

Intervention Type DRUG

Placebo

14 day repeated BID doses

Intervention Type DRUG

PF-06305591

14 day repeated BID doses

Intervention Type DRUG

PF-06305591

relative bioavailability tablet vs. solution and food effect at 50mg dose

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy male or female subjects of non childbearing potential, between the ages of 21 and 55 years, inclusive. Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurement, 12 lead ECG and clinical laboratory tests

Exclusion Criteria

* Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at the time of dosing).
* Any condition possibly affecting drug absorption (eg, gastrectomy).
Minimum Eligible Age

21 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Pfizer

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Pfizer CT.gov Call Center

Role: STUDY_DIRECTOR

Pfizer

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Pfizer Investigational Site

Brussels, , Belgium

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Belgium

Related Links

Access external resources that provide additional context or updates about the study.

https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B5281002&StudyName=Safety%20and%20Tolerability%20Study%20of%20Multiple%20Doses%20of%20PF-06305591

To obtain contact information for a study center near you, click here.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

B5281002

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Doses of PF-06852231 in Healthy Subjects
NCT03217604 COMPLETED PHASE1
Study To Evaluate Safety, Tolerability, And Pharmacokinetics Of PF-06473871 In Normal Healthy Adults
NCT01753791 COMPLETED PHASE1
A Study To Evaluate The Safety And Tolerability Of Different Doses Of PF-03049423 In Healthy Adult Volunteers And Healthy Older Volunteers
NCT01161069 COMPLETED PHASE1
Group Study To Investigate The Safety, Toleration And Pharmacokinetics Of Multiple Oral Doses Of PF-04531083 In Healthy Subjects
NCT01012310 COMPLETED PHASE1
A Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-04629991 in Healthy Volunteers
NCT00797342 COMPLETED PHASE1
Study of Single and Multiple Ascending Doses of PF-07059013 in Healthy Adult Participants
NCT04323124 TERMINATED PHASE1
A Study to Learn How the Study Medicine PF-07899895 Are Tolerated and Act in the Body of Healthy Adults
NCT06137729 TERMINATED PHASE1
A Multiple Dose Study Of PF-06678552 In Healthy Subjects
NCT02079922 COMPLETED PHASE1
Evaluation Of Safety, Tolerability And Pharmacokinetics Of Single And Multiple Doses Of Compound PF-06823859
NCT02766621 COMPLETED PHASE1
A Phase 1 Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Pf-05230907 In Healthy Volunteers
NCT01897142 COMPLETED PHASE1
A Study to Evaluate Safety, Toleration and Time Course of Plasma Concentration of Multiple Oral Doses of PF-06372865 in Healthy Subjects of Two AgeGroups, Aged 18-55 Years (Group 1) and Aged 56-75 Years (Group 2)
NCT02070289 COMPLETED PHASE1
A Study In Healthy People To Evaluate Safety, Toleration And Time Course Of Plasma Concentration Of Multiple Oral Doses Of PF-04895162
NCT01691274 COMPLETED PHASE1
A First In Human Study In Healthy People To Evaluate Safety, Toleration And Time Course Of Plasma Concentration Of Single Oral Doses Of PF-06273340
NCT01601834 COMPLETED PHASE1
Study of Single Ascending Doses of PF-07081532 in Healthy Adult Participants
NCT04148209 COMPLETED PHASE1
A Study to Evaluate Safety, Toleration and Time Course of Plasma Concentration of Multiple Oral Doses of PF-06273340 in Healthy Subjects of Two AgeGroups, Aged 18-55 Years (Group 1) and Aged 56-75 Years (Group 2)
NCT01934738 COMPLETED PHASE1
Single Dose Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Study Of PF-06291874 In Healthy Adult Subjects
NCT01794364 COMPLETED PHASE1
A Study to Learn How Different Amounts of the Study Medicine Called PF-07940369 Are Tolerated and Act in the Body in Healthy Adults.
NCT06532383 COMPLETED PHASE1
Study In Healthy Adult Volunteers To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of PF-04427429
NCT01117233 COMPLETED PHASE1
A Study To Assess The Safety, Tolerability And Pharmacokinetics Of PF-06282999 Administered Orally In Healthy Adult Subjects
NCT01626976 COMPLETED PHASE1
A Study To Observe Safety And Blood Concentrations Of PF-06649751 During And Following The Oral Administration Of Multiple Doses Of PF-06649751 In Healthy Adult Western and Japanese Volunteers
NCT02066909 COMPLETED PHASE1
STUDY OF PF-07321332 IN HEALTHY PARTICIPANTS
NCT04756531 COMPLETED PHASE1
A Study To Assess The Safety, Tolerability, And Pharmacokinetics (PK) Of Multiple Doses Of PF-06865571 In Healthy, Including Overweight And Obese, Adult Subjects
NCT03230383 COMPLETED PHASE1
Study To Evaluate The Safety, Tolerability, And Pharmacokinetics Of Oral Pf-06650833 In Healthy Subjects
NCT02485769 COMPLETED PHASE1
A Single Dose Study Of PF-06678552 In Healthy Subjects
NCT01992614 COMPLETED PHASE1
A Phase 1 Study To Evaluate The Safety And Tolerability Of Different Doses Of PF-03893787 In Healthy Adult Volunteers
NCT00992342 COMPLETED PHASE1